Core AI Holdings, Inc. (NASDAQ: CHAI) announced the appointment of Arie Goor as Chief Financial Officer, effective July 1, 2026.

Goor, 43, brings more than 15 years of executive financial leadership experience in corporate finance, capital markets, and strategic transactions across the biotechnology, medical device, and technology sectors.

Before joining Core AI Holdings, Goor served as CFO of NYSE-listed Regentis Biomaterials (RGNT) from October 2022 to January 2026, and as CFO of Revium Rx from June 2023 to May 2026. He has led initial public offerings and capital markets transactions on exchanges including Nasdaq, the Australian Securities Exchange, the TSX Venture Exchange, and the Tel Aviv Stock Exchange.

Goor also serves as a financial advisor to Nasdaq-listed Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) and Polyrizon Ltd. (NASDAQ: PLRZ), advising on corporate finance, SEC reporting, governance, and capital markets strategy.

Since 2018, Goor has served as Head of the IPO and M&A Department at Shimony Financial Services. He previously worked as an Audit Manager at Ernst & Young, focusing on publicly traded and emerging growth companies.

Goor holds an MBA in Financial Management from Tel Aviv University and a B.A. in Accounting and Economics from the Hebrew University of Jerusalem. He has held a Certified Public Accountant license since 2012.

"Arie brings a proven track record of financial leadership, capital markets expertise, and strategic execution," said Aitan Zacharin, CEO of Core AI Holdings, in a statement based on the company's press release.